Bcat1 siRNA_Lentivectors
- Known as:
- Bcat1 siRNA_Lentivectors
- Catalog number:
- i065399b
- Product Quantity:
- 500ng
- Category:
- -
- Supplier:
- ABM
- Gene target:
- Bcat1 siRNA_Lentivectors
Related genes to: Bcat1 siRNA_Lentivectors
- Gene:
- BCAT1 NIH gene
- Name:
- branched chain amino acid transaminase 1
- Previous symbol:
- BCT1
- Synonyms:
- -
- Chromosome:
- 12p12.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-03-07
Related products to: Bcat1 siRNA_Lentivectors
Related articles to: Bcat1 siRNA_Lentivectors
- Myofibroblasts are the cells responsible for collagen production, leading to tissue fibrosis. Because 20.5% of the total amino acids in collagen are proline, myofibroblasts must acquire a well-developed proline-producing mechanism during their differentiation. However, the detailed mechanism for myofibroblasts to acquire and keep the developed proline biosynthesis machinery remains obscure. Here, we show branched-chain amino acid transaminase 1 (Bcat1) is up-regulated in a substantial subset of Postn-expressing proto-myofibroblast-like fibroblasts, transitional cells en route to fully differentiated myofibroblasts, as well as in myofibroblasts in the fibrotic heart and liver of mice and humans and promotes the proline production. The branched-chain amino acid (BCAA) production by BCAT1 promotes SMAD3 phosphorylation via HDAC5 phosphorylation at Ser488, thereby enhancing SMAD3-dependent transcription of proline biosynthesis-related genes, Aldh18a1, Pycr1, and Eprs, in proto-myofibroblast-like fibroblasts and myofibroblasts. In BCAT1-deficient mice, expression of proline biosynthesis-related genes is significantly attenuated in their hearts after myocardial infarction, resulting in decreased cardiac fibrosis. Moreover, BCAT1 inhibitor treatment of mice with myocardial infarction reduces cardiac fibrosis. Our results identified a BCAT1-mediated pathway that promotes collagen production via proline biosynthesis regulation in proto-myofibroblast-like fibroblasts and myofibroblasts, which may provide a therapeutic target for cardiac fibrosis. - Source: PubMed
Publication date: 2026/07/16
Takizawa NoburoHironaka TakanoriWatanabe HayatoSuetsugu HarunaYoshioka KeisukeHorii YumaNagata YuriMatoba HiroakiKosako HidetakaHamase KenjiHirai GoNakaya Michio - Based on emerging evidence implicating branched-chain aminotransferase 1 (BCAT1) in tumorigenesis from animal and cellular studies, this study aimed to systematically evaluate its oncogenic role through a pan-cancer analysis to address the lack of comprehensive pan-cancer investigations in the literature. Using datasets from The Cancer Genome Atlas and the Genotype-Tissue Expression project, we analyzed BCAT1 expression, prognosis, genetic alterations, immune infiltration, and functional enrichment across 33 cancer types. The primary endpoints were overall survival (OS) and disease-free survival (DFS). Statistical significance was primarily defined as P < .05. For analyses involving multiple correlations across cancer and immune cell types, the false discovery rate < 0.05 was applied. BCAT1 was significantly upregulated in most malignancies, and high expression was associated with worse OS and DFS in multiple cancer types. BCAT1 expression correlated with reduced CD8+ T cell infiltration and increased cancer-associated fibroblast accumulation across several tumors. Enrichment analyses suggested BCAT1 involvement in RNA metabolism and intracellular protein processing. BCAT1 was significantly upregulated in most malignancies, and high expression was associated with worse OS and DFS in multiple cancer types, including adrenocortical carcinoma (hazard ratio = 6.3) and lower-grade glioma (hazard ratio = 2.6) (all log-rank P < .05), highlighting its potential as a pan-cancer biomarker and therapeutic target. The present findings are associative and require further experimental and external validation. - Source: PubMed
Wang BinbinWei YizeDong MingjieGao CongrongYue HuiSun Ming - Colorectal cancer (CRC) screening is crucial for early detection, yet the invasiveness of the gold-standard colonoscopy limits compliance. To address the limitation, this study proposes a novel multi-target free DNA methylation model and evaluated its risk stratification performance for CRC in high-risk populations. - Source: PubMed
Publication date: 2026/07/29
Li YingLi ShibaoWang HuiFeng Qian - Head and neck squamous cell carcinoma (HNSCC) poses a significant global health challenge, characterized by low survival rates and frequent metastasis. Conventional therapies are often restricted by systemic toxicity and drug resistance, positioning natural bioactive extracts like Total Glucosides of Paeony (TGP) as promising therapeutic alternatives. While the amino acid transporter SLC7A5 is known to drive tumor proliferation by facilitating leucine uptake and activating the mTOR signaling pathway, the specific interaction between TGP and this SLC7A5/mTOR axis in HNSCC has not been fully elucidated. - Source: PubMed
Publication date: 2026/07/11
Li YuanqiangHu GaofengNiu WenyuanZhang LizhuoGe JiamingXuan JieYu XuefeiMa ShangLi MengjiaZhang ZiqiangLuo KeJia XingLi Qinglin - To evaluate the diagnostic performance and clinicopathologic relevance of a multi-locus circulating tumor DNA methylation assay, in this prospective, single-center, case-control exploratory study, we enrolled 35 patients with colorectal cancer undergoing surgery and 57 healthy controls undergoing screening colonoscopy at the Asan Medical Center, Seoul, Republic of Korea between July 2024 and January 2025. Peripheral blood was collected before surgery or colonoscopy, and circulating tumor DNA methylation was analyzed using a multi-locus panel targeting Septin9, IKZF1, BCAT1, Septin9-2, BCAN, and VAV3. The main outcomes were test accuracy (sensitivity, specificity, and area under the curve [AUC]) and associations between methylation marker positivity and clinicopathologic features. Circulating tumor DNA was positive in 74.3% of the patients and 12.3% of controls, yielding a sensitivity of 74.3%, specificity of 87.7%, and an AUC of 0.837, whereas serum carcinoembryonic antigen exhibited lower sensitivity (25.7%). Sensitivity in stage I disease was limited (36.4%). Circulating tumor DNA-positive tumors were larger (5.7 cm vs. 2.2 cm, < 0.001) and had more advanced T and N stages. The number of positive markers increased with pathologic stage ( = 0.003). Individual marker analysis revealed that BCAT1, Septin9-2, and VAV3 were associated with higher T stage, whereas BCAN positivity was linked to nodal metastasis. The six-marker circulating tumor DNA methylation assay demonstrated acceptable diagnostic accuracy, with multi-locus patterns associated with tumor burden and invasive features. However, sensitivity for early-stage disease was limited. The assay may serve as a complementary tool for screening and risk stratification. - Source: PubMed
Publication date: 2026/06/25
Lee HayoungKang Jae CheolPark In JaKim Gwang-UnHyun HwiMin Na YoungJeon SungwonKim Byoung-Chul